---
figid: PMC8581795__jamadermatol-e214084-g002
pmcid: PMC8581795
image_filename: jamadermatol-e214084-g002.jpg
figure_link: /pmc/articles/PMC8581795/figure/dbr210019f2/
number: Figure 2.
figure_title: Clinical Course and Molecular Features of Patients With Persistent Erythema
  Multiforme (PEM)
caption: A, Approximate change in disease activity in patients 1-4. B, Volcano plot
  of RNA-seq data in EM associated with tofa use in patient 4. C, Volcano plot of
  IPA on RNA-seq data. D, Cytokine levels in TIF from PEM skin biopsy specimens as
  a function of tofa in patient 4. E, IFNG and IL15 RISH in 12 EM samples compared
  with 7 controls (normal skin).d/c denotes discontinued; EM, erythema multiforme;
  IFN-Î³, interferon gamma; IL-15, interleukin 15 ; IPA, Ingenuity Pathway Analysis;
  JAK, Janus kinase; RISH, RNA in situ hybridization; RISH quant, RISH quantification;
  RNA-seq, RNA sequencing; STAT, signal transducer and activator of transcription;
  TIF, tissue interstitial fluid; tofa, tofacitinib; and TNF, tumor necrosis factor.
article_title: Treatment of Persistent Erythema Multiforme With Janus Kinase Inhibition
  and the Role of Interferon Gamma and Interleukin 15 in Its Pathogenesis.
citation: Michael J. Murphy, et al. JAMA Dermatol. 2021 Dec;157(12):1-6.
year: '2021'

doi: 10.1001/jamadermatol.2021.4084
journal_title: JAMA Dermatology
journal_nlm_ta: JAMA Dermatol
publisher_name: American Medical Association

keywords:
---
